J&J Eprex Sales Stabilize As Aplasia Cases Decline; Patient Registry Planned
Executive Summary
Johnson & Johnson is focusing on rebuilding Eprex now that quarterly sales have stabilized for the first time since a labeling revision regarding pure red cell aplasia in chronic renal failure patients
You may also be interested in...
J&J Describes Eprex Safety Findings In Petition Against Follow-On Biologics
Johnson & Johnson believes that safety issues triggered by a change in stabilizers used in production of the erythropoietin Eprex support the biotechnology industry's position that "follow-on" biologics need separate clinical trials
J&J Describes Eprex Safety Findings In Petition Against Follow-On Biologics
Johnson & Johnson believes that safety issues triggered by a change in stabilizers used in production of the erythropoietin Eprex support the biotechnology industry's position that "follow-on" biologics need separate clinical trials
J&J Puts A Cork In Eprex Problem: Teflon-Coated Stopper May Solve PRCA
Johnson & Johnson believes that the incidence of pure red cell aplasia seen with the overseas epoetin brand Eprex was most likely caused by leaching from rubber stoppers used in vials of the product